论文部分内容阅读
目的:探讨膜突蛋白(MSN)在前列腺癌中的诊断价值。方法:应用蛋白组学二维荧光差异凝胶电泳技术对比前列腺癌与前列腺增生组织中MSN表达情况。免疫组织化学法进一步检测61例前列腺癌与24例前列腺增生患者标本中MSN蛋白表达,并分析其与临床病理特征之间关系。结果:蛋白组学结果显示,相对于增生组织,前列腺癌组织中MSN蛋白表达下调(P=0.032)。免疫组化结果显示,前列腺癌组织中MSN表达低于良性增生组织(P=0.018),其表达强度与癌组织的Gleason评分呈负相关(P=0.002),但与年龄(P=0.488)、肿瘤临床分期(P=0.313)、病理分级(P=0.720)无明显相关。结论:MSN蛋白水平的降低是前列腺癌细胞恶性程度升高的标志,其在前列腺癌的诊断中具有一定价值。
Objective: To investigate the diagnostic value of membrane protein promo (MSN) in prostate cancer. Methods: Two-dimensional fluorescence difference gel electrophoresis was used to compare the expression of MSN in prostate cancer and benign prostatic hyperplasia. Immunohistochemistry was used to further detect the expression of MSN protein in 61 cases of prostate cancer and 24 cases of benign prostatic hyperplasia, and to analyze the relationship between them and clinicopathological features. Results: The results of proteomics showed that the expression of MSN protein in prostate cancer tissues was down-regulated (P = 0.032) compared with that in proliferative tissues. Immunohistochemical results showed that the expression of MSN in prostate cancer tissues was lower than that in benign hyperplasia tissues (P = 0.018), and the expression level was negatively correlated with Gleason score (P = 0.002), but not with age (P = 0.488) Tumor clinical stage (P = 0.313), pathological grade (P = 0.720) no significant correlation. Conclusion: The decrease of the protein level of MSN is a marker of the malignant degree of prostate cancer cells, which has a certain value in the diagnosis of prostate cancer.